Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
August 20, 2026
02:30 PM - 03:30 PM ET
September 24, 2026
03:30 PM - 04:30 PM ET
September 03, 2026
02:00 PM - 03:00 PM ET
The Future of mCSPC: Molecular Profiling and Biomarker-Directed Therapies
Neeraj Agarwal, MD, FASCO
Rana McKay, MD
EHA 2026: Sonrotoclax Plus Zanubrutinib in Frontline CLL
Chan Y. Cheah, MBBS
ADT Intensification: The Evidence You Can’t Afford to Miss
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Molecular Profiling in mHSPC: Informing Treatment Selection
IBD Masterclass: Choosing the Right IBD Therapy - A Patient-Clinician Connection
Florence Odufalu, MD
Ugo Iroku, MD, MHS
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
Aditya Bardia, MD, MPH, FASCO
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
A Q-Challenge™ Replay: Advancing Precision Diagnosis and Treatment Strategies in Acromegaly
Maria Fleseriu, MD, FACE
Shlomo Melmed, MBChB
Elise M. Brett, MD, FACE
Rapid Data Pulses From ASCO 2026: Emerging Data on Oral Targeted Strategies in Breast Cancer
Erica L. Mayer, MD, MPH
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
Sara A. Hurvitz, MD, FACP
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Tiffany Traina, MD, FASCO
The Future of Biologic Treatment in IBD: What’s on the Horizon
Michael Dolinger, MD, MBA
David T. Rubin, MD
Small Molecules in IBD: JAK Inhibitors and S1P Modulators
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.